Form D · Pharmaceuticals
Azora Therapeutics, Inc.
Encino, CA · CIK 0001866534
Offering snapshot reported Aug 9, 2023 · SEC filing
- Reported sold
- $581K Offering amount: $596K
- Investors reported
- 11 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 2, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 9, 2023 | Initial | $581,449 | No comparison | 11 | SEC filing |
| Jun 14, 2021 | Initial | $7,734,902 | No comparison | 108 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-489214
Source: Form D, filed Aug 9, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Dennis Brown | Director |
| Matt Davidson | Director, Executive |
| Matthew Davidson | Director, Executive |
| Julie Saiki | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
4267 Valley Meadow Road
Encino, CA, 91436
Encino, CA, 91436